Dianthus Therapeutics (DNTH) Current Deferred Revenue (2022 - 2025)
Dianthus Therapeutics (DNTH) posted quarterly Current Deferred Revenue of $1.2 million for Q4 2025, up 148.02% year-over-year from $479000.0 in Q4 2024, and up 24.53% quarter-over-quarter from $954000.0 in Q3 2025.
Dianthus Therapeutics (DNTH) Current Deferred Revenue (2022 - 2025) Analysis & Trends
Dianthus Therapeutics' Current Deferred Revenue history runs 4 years deep, the most recent figure standing at $1.2 million for Q4 2025.
- In Q4 2025, Current Deferred Revenue rose 148.02% year-over-year to $1.2 million; the TTM figure through Dec 2025 stood at $1.2 million (up 148.02% YoY), while the FY2025 annual figure was $1.2 million, up 148.02% from the prior year.
- Current Deferred Revenue for Q4 2025 stood at $1.2 million, up from $954000.0 in the prior quarter.
- The five-year high for Current Deferred Revenue was $1.2 million in Q4 2025, with the low at $100000.0 in Q4 2022.
- The 4-year median for Current Deferred Revenue is $289500.0 (2022), against an average of $407900.0.
- The sharpest annual moves came in 2024 and 2025: Current Deferred Revenue changed 0.0% in 2024, then jumped 854.0% in 2025.
- Dianthus Therapeutics' Current Deferred Revenue stood at $100000.0 in 2022, then changed by 0.0% to $100000.0 in 2023, then jumped by 379.0% to $479000.0 in 2024, then jumped by 148.02% to $1.2 million in 2025.
- Business Quant data shows DNTH's Current Deferred Revenue at $1.2 million in Q4 2025, $954000.0 in Q3 2025, and $479000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Dianthus Therapeutics | 4.97 Bn | 4.57 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.19 Mn |
| Sep 30, 2025 | 954,000.00 |
| Jun 30, 2025 | 479,000.00 |
| Mar 31, 2025 | 479,000.00 |
| Dec 31, 2024 | 479,000.00 |
| Sep 30, 2024 | 100,000.00 |
| Jun 30, 2024 | 100,000.00 |
| Mar 31, 2024 | 100,000.00 |
| Sep 30, 2023 | 100,000.00 |
| Dec 31, 2022 | 100,000.00 |